Dogwood Therapeutics, Inc (NASDAQ:DWTX) Sees Significant Drop in Short Interest

Dogwood Therapeutics, Inc (NASDAQ:DWTX – Get Free Report) saw a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 38,895 shares, a decrease of 47.6% from the September 15th total of 74,269 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 64,451 shares, the short-interest ratio is currently 0.6 days.

Dogwood Therapeutics Price Performance

Shares of DWTX stock traded up $0.03 on Wednesday, reaching $1.33. 16,074 shares of the stock were exchanged, compared to its average volume of 76,079. Dogwood Therapeutics has a one year low of $1.28 and a one year high of $7.04. The stock has a market cap of $45.07 million, a PE ratio of -0.15 and a beta of 1.92. The stock has a 50 day moving average price of $1.89 and a 200 day moving average price of $1.73.

Get Dogwood Therapeutics alerts:

Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.20). On average, research analysts expect that Dogwood Therapeutics will post -0.80 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DWTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Friday, July 24th. HC Wainwright reaffirmed a “buy” rating on shares of Dogwood Therapeutics in a report on Wednesday, September 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $12.00.

View Our Latest Report on DWTX

About Dogwood Therapeutics

(Get Free Report)

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with herpesvirus reactivation. The company’s research is aimed at addressing chronic conditions for which viral activity may contribute to symptoms and disease progression.

Dogwood’s lead investigational product is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory drug. The therapy has been studied as a potential treatment for fibromyalgia, and the company has also evaluated its broader application in conditions such as long COVID.

The company was formerly known as Virios Therapeutics and adopted the Dogwood Therapeutics name as it expanded its focus on antiviral drug development.

Featured Stories

• Five stocks we like better than Dogwood Therapeutics
• High Voltage Returns: Navitas Rewires AI Data Centers
• Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
• Albertsons Is Betting on a Turnaround—But Will It Pay Off?
• Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit

Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.